实用肝脏病杂志 ›› 2012, Vol. 15 ›› Issue (5): 392-393.doi: 10.3969/j.issn.1672-5069.2012.04.007

• 丙型肝炎 • 上一篇    下一篇

普通干扰素1b联合利巴韦林治疗非1b型慢性丙型肝炎患者临床观察

雷华, 禹蔚琴, 田波, 戴静毅, 王晴晴, 柏保利, 庄林   

  1. 650041 昆明市第三人民医院肝病科
  • 收稿日期:2012-05-04 出版日期:2012-10-10 发布日期:2017-03-09
  • 通讯作者: 庄林,E-mail:zlinkm@126.com
  • 作者简介:雷华 女,39岁,副主任医师。E-mail:kmleihua@163.com

Combination of interferon alfa-1b and ribavirin in the treatment of patients with chronic hepatitis C of non-1b

Lei Hua, Yu Weiqin, Tian Bo, et al.   

  1. Department of Liver Diseases,Third Municipal People’s Hospital,Kunming 650041
  • Received:2012-05-04 Online:2012-10-10 Published:2017-03-09
  • Contact: Zhuang Lin,E-mail:zlinkm@126.com

摘要: 目的 探讨不同基因型HCV感染者对普通干扰素联合利巴韦林治疗的疗效。方法 应用型特异性探针杂交法检测106例慢性丙型肝炎患者HCV基因型。应用普通干扰素联合利巴韦林治疗,观察病毒学应答情况。结果 在106例患者中,以HCV 3b(45.3%)、1b(20.8%)和3a(18.9%)型为主,6a(9.4%)和2a(5.7%)型次之;在22例1b型感染者,只有9例接受本治疗方案,82例非1b型感染者完成治疗。非1b型患者的RVR和EVR分别为50%和86.6%;在1b型HCV感染者,22.2%(2/9)获得SVR,而非1b型HCV感染者,76.8%(63/82)获得SVR。结论 普通干扰素联合利巴韦林治疗非1b型慢性丙型肝炎患者疗效较好。

关键词: 慢性丙型肝炎, HCV基因型, 干扰素α1b, 利巴韦林, 疗效

Abstract: Objective To investigate the efficacies of interferon alfa-1b and ribavirin in treatment of patients with chronic hepatitis C of different genotypes. Methods The genotypes of hepatitis C virus in 106 patients with hepatitis C were detected by genotype-specific probes. The patients with hepatitis C were treated with interferon alfa-1b and ribavirin for 48 weeks. Results Out of 106 patients with hepatitis C,the HCV genotype 3b accounted for 45.3%,1b for 20.8%,and 3a for 18.9%,while we still detected some 6a(9.4%)and 2a(5.7%) positive;Nine out of 22 patients with hepatitis C of 1b and other 82 with non-1b finished the regimen;the rapid virological response and early virological response in patient with non-1b were 50% and 86.6%,respectively;22.2%(2/9)of 1b infected patients got sustained virological response,while 76.8%(63/82)of non-1b got SVR。Conclusion Interferon alfa-1b and ribavirin regimen can be selected for hepatitis C patients with non-1b infection.

Key words: Hepatitis C, HCV genotypes, Interferon alfa, Ribavirin, Efficacy